Salute e Benessere
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
U.S. Apixaban sales reached $26.1 billion in 2024*, and the global anticoagulant market continues to expand. Given these trends, TAH3311 is well positioned as a safer and more accessible treatment option. TAHO Pharmaceuticals plans to file regulatory submissions in both the United States and
Europe in Q3 2025. At the same time, the company is actively pursuing strategic collaboration opportunities with international partners to accelerate TAH3311's global launch.
*Source: IQVIA 2024
Apixaban (co-developed by BMS and Pfizer under the brand name Eliquis®) is a direct factor Xa inhibitor and has been approved for clinical use in several thromboembolic disorders, including stroke prevention in non-valvular atrial fibrillation, thromboprophylaxis after hip/knee replacement, and the treatment and prevention of deep vein thrombosis or pulmonary embolism. With notable safety advantages, it is the leading novel oral anticoagulant (NOAC).
Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial Delivery System (TDS) to overcome the limitations of existing drugs and develop innovative dosage forms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO's diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan .
Media Contact:
TAHO Pharmaceuticals
Website: https://www.tahopharma.com/en/
+886-2-2659-8515
ir@tahopharma.com
View original content:https://www.prnewswire.co.uk/news-releases/taho-pharmaceuticals-reports-positive-results-from-pivotal-study-of-tah3311-the-first-oral-dissolving-film-anticoagulant-302377988.html